|
15 Sep 2025 |
Aarti Industries
|
Consensus Share Price Target
|
389.40 |
458.23 |
- |
17.68 |
hold
|
|
|
|
|
26 Aug 2019
|
Aarti Industries
|
CD Equisearch
|
389.40
|
1741.00
|
1507.35
(-74.17%)
|
Pre-Bonus/ Split |
Accumulate
|
|
|
Stifled by slowdown in exports more so in the automobile segment, revenues of specialty chemicals grew by a dismal 5.5% last quarter - though on constant raw material prices the increase by ~9%. Yet revenues from its not so large pharmaceutical business rose by a sturdy 27.7% to Rs 191.14 crs...
|
|
19 Aug 2019
|
Aarti Industries
|
BP Wealth
|
389.40
|
1747.00
|
1569.85
(-75.20%)
|
Target met |
Sell
|
|
|
Aarti Industries Ltd (AIL), for Q1FY20, reported steady set of numbers. Revenue has grown by 8.8% (on adjusting HPC business revenue) mainly due to higher utilisation across all segments. EBITDA grew by 26.1%YoY to INR2.36bn with 439bps improvement in margins to 21.7% on account of increasing share of value added and high margin products. Net profit grew at a higher pace of 53.9% to...
|
|
16 Aug 2019
|
Aarti Industries
|
Geojit BNP Paribas
|
389.40
|
1572.00
|
1591.65
(-75.53%)
|
Target met |
Sell
|
|
|
Given strong demand outlook in domestic & export market in the long term, the capacity augmentation is on track. We believe that capacity addition, focus on high margin products and robust off-take from Specialty chemicals and Pharma segment, will continue to drive profitability. However, given weak macro economic situation and slowdown in...
|
|
21 Jun 2019
|
Aarti Industries
|
Axis Direct
|
389.40
|
1826.00
|
1772.05
(-78.03%)
|
Target met |
Hold
|
|
|
In Q4FY19, Aarti Industries reported std. revenue of Rs. 1,211 Cr (up 18% Y-o-Y, down 4% Q-o-Q), EBITDA of Rs. 238 Cr (up 31% Y-o-Y, down 4% Q-o-Q). PAT for the quarter stood at Rs. 125 cr (up 47% Y-o-Y, down 6% Q-o-Q).
|
|
23 May 2019
|
Aarti Industries
|
Geojit BNP Paribas
|
389.40
|
1949.00
|
1730.50
(-77.50%)
|
Pre-Bonus/ Split |
Buy
|
|
|
Q4FY19 Revenue & PAT grew by robust 18% & 47% YoY led by broad based growth across segments. EBITDA grew by 31% YoY, whereas EBITDA margin improved by 200bps YoY to 19.5% due to high margin product mix. To invest Rs1,200cr for capacity augmentation in FY20E given strong demand outlook in domestic & export market....
|
|
23 May 2019
|
Aarti Industries
|
BP Wealth
|
389.40
|
1881.00
|
1730.50
(-77.50%)
|
Target met |
Hold
|
|
|
Aarti Industries Ltd (AIL), for Q4FY19, reported strong set of numbers. Revenue has grown by 17.7% mainly due to healthy performance across all segments. EBITDA grew by 31.4%YoY to INR2,369mn with 205bps improvement in margins to 19.6% on account of increasing share of value added and high margin products. Net profit grew at a higher pace of 46.9% to INR 1245mn, due to slower growth in depreciation and interest expenses bolstered by operationally strong performance. Overall volumes in the specialty chemical segment grew by 3% YoY in Q4FY19 (FY19: 8%); For FY20, the management has guided for midteen volume growth. Moreover, they have alluded an increase in realization in many of the products leading to a better margin profile, which would aid in supporting growth going...
|
|
22 Feb 2019
|
Aarti Industries
|
Axis Direct
|
389.40
|
1599.00
|
1407.00
(-72.32%)
|
Target met |
Buy
|
|
|
Growth in Specialty Chemical Industry, Well Diversified Portfolio and Global Presence, Benzene business; the cash cow, Toluene value chain to drive growth, Pharma at inflection point
|
|
06 Feb 2019
|
Aarti Industries
|
Geojit BNP Paribas
|
389.40
|
1787.00
|
1619.30
(-75.95%)
|
Target met |
Hold
|
|
|
EBITDA grew by 39% YoY, whereas EBITDA margin improved by 150bps YoY to 19.5% due to high margin product mix. Capacity addition, focus on high margin products and robust off-take...
|
|
05 Feb 2019
|
Aarti Industries
|
BP Wealth
|
389.40
|
1866.00
|
1677.00
(-76.78%)
|
Target met |
Hold
|
|
|
|
|
28 Nov 2018
|
Aarti Industries
|
CD Equisearch
|
389.40
|
1704.00
|
1480.00
(-73.69%)
|
Target met |
Accumulate
|
|
|
Thanks to higher raw material prices and increasing share of high margin products, Aarti's speciality chemicals gross revenues rose 50.4% (volume growth just 10%) to Rs 1039.10 crs ($148.4m), probably the highest level ever; nitrochlorobenzene production barely budged last quarter , underscoring impact of high value addition and pass-through of higher raw material prices. Despite MTM loss of Rs 22.59 crs ($3.2m) on forward contracts, EBIT margin surged to 20.2% from 18.6% in the same period a year back (17.5% in Q1FY19). Volume off take was scarcely suppressed by...
|